Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)

v3.22.1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating Expenses:    
Research and development $ 658,939 $ 99,899
Research and development - related parties 47,718 267,053
General and administrative 2,969,151 2,542,231
General and administrative - related parties 5,261 39,120
Total Operating Expenses 3,681,069 2,948,303
Loss From Operations (3,681,069) (2,948,303)
Other Income (Expense):    
Gain on settlement of liabilities 723,764
Interest expense (7,414) (112,933)
Interest income (expense) - related parties 4,562 (13,949)
Loss on extinguishment of convertible notes payable, net (9,737)
Change in fair value of derivative liabilities 5,230,114 (13,229,308)
Change in fair value of accrued issuable equity 17,520 (9,405)
Offering costs allocated to warrant liabilities (604,118)
Total Other Income (Expense), Net 5,244,782 (13,255,686)
Income (Loss) Before Income Taxes 1,563,713 (16,203,989)
Income tax benefit   5,404
Net Income (Loss) 1,563,713 (16,198,585)
Other Comprehensive Income (Loss):    
Foreign currency translation adjustments (728,081) 189,348
Total Comprehensive Income (Loss) $ 835,632 $ (16,009,237)
Basic and Diluted Net Income (Loss) per Common Share    
Basic (in Dollars per share) $ 0.05 $ (0.58)
Diluted (in Dollars per share) $ 0.05 $ (0.58)
Weighted Average Number of Common Shares Outstanding:    
Basic (in Shares) 34,059,927 27,953,302
Diluted (in Shares) 34,068,762 27,953,302